Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
暂无分享,去创建一个
John Wong | S. Fan | R. Poon | C. Lo | W. Tso | J. Wong | Chung-Mau Lo | Chi-Leung Liu | Sheung-Tat Fan | Chi-leung Liu | C. Lam | Wai-Kuen Tso | Ronnie Tung-Ping Poon | Chi-Ming Lam | Henry Ngan | H. Ngan
[1] C. Moertel,et al. Primary liver cancer. An eastern cooperative oncology group trial , 1984, Cancer.
[2] S. Ishiguro,et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge , 1987, Cancer.
[3] T. Iga,et al. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients. , 1985, The American journal of gastroenterology.
[4] M. Doffoel,et al. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patients , 1991, Hepatology.
[5] M. Biselli,et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian Experience , 1995, Cancer.
[6] K. Hasuo,et al. A 5‐year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma , 1989, Hepatology.
[7] K. Franssila,et al. Regional intra‐arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study , 1986, Cancer.
[8] H. Hasegawa,et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.
[9] K. Stokes,et al. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization , 1993, Cancer.
[10] M. Morino,et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. , 1992, American journal of surgery.
[11] M. Ducreux,et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.
[12] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[13] M. Tatsuta,et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. , 1989, Gastroenterology.
[14] J. Bruix,et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution , 1998, Hepatology.
[15] M. Schwartz,et al. Treatment of Hepatocellular Carcinoma Associated with Cirrhosis in the Era of Liver Transplantation , 1998, Annals of Internal Medicine.
[16] B. Jones,et al. Non-operative arterial embolisation in primary liver tumours. , 1979, British medical journal.
[17] S. Fan,et al. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. , 1993, Clinical radiology.
[18] E. ArévaloJiménez,et al. Primary liver cancer , 1985 .
[19] D. Cella,et al. Eastern Cooperative Oncology Group (ECOG). , 1996, Journal of the National Cancer Institute. Monographs.
[20] J. Bruix,et al. Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients , 1990, Hepatology.
[21] Lu-Yu Hwang,et al. HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.
[22] J. Bruix,et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials , 1999, Hepatology.
[23] J. Bruix,et al. Treatment of hepatocellular carcinoma. , 2006, Critical reviews in oncology/hematology.
[24] S. Chevret,et al. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. , 1995, The New England journal of medicine.
[25] S. Beningfield,et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. , 1993, Gut.
[26] D.,et al. Regression Models and Life-Tables , 2022 .
[27] O. Nanni,et al. Hepatocellular carcinoma. Prognostic factors and survival analysis in 135 Italian patients. , 1992, Journal of hepatology.
[28] A. Roche,et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. , 1990, Journal of hepatology.
[29] Y. Yen,et al. Ethnic differences in the behavior of hepatocellular carcinoma , 1999, Cancer.
[30] K. Ohnishi,et al. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha‐fetoprotein levels. Analysis of 606 patients , 1989, Cancer.
[31] D. Neuberg,et al. An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92 , 2004, Investigational New Drugs.
[32] Y. Liaw,et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. , 1988, Gastroenterology.
[33] A. Moles,et al. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival , 2000, Hepatology.
[34] T. Sodeyama,et al. [Global epidemiology of hepatocellular carcinoma]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.